Enhanced blood–brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles

Meng Liang, Chun‐Hong Gao, Yuli Wang, Wei Gong, Shiyao Fu, Lin Cui, Zhenhan Zhou, Xiaoyang Chu, Yue Zhang, Qianqian Liu, Xiong Zhao, Baoquan Zhao, Meiyan Yang, Zhiping Li, Chunrong Yang, Xiangyang Xie, Chunsheng GaoDrug 2018 · DOI

TL;DR

This paper presents a novel drug delivery system, T7 peptide-modified low-density lipoprotein particles (T7-LDL), designed to overcome the blood-brain barrier (BBB) and specifically target glioma cells. This dual-targeting approach significantly enhances the delivery and therapeutic efficacy of the chemotherapy drug vincristine sulfate (VCR) in both in vitro and in vivo models, offering a promising strategy for treating this aggressive brain cancer.

What Problem Does This Paper Address?

Glioma, a type of brain cancer, is notoriously difficult to treat effectively due to two major challenges: the blood-brain barrier (BBB) and the non-specific nature of current therapies. The BBB acts as a formidable gatekeeper, severely limiting the passage of most therapeutic drugs from the bloodstream into the brain. Furthermore, conventional chemotherapy drugs often exhibit broad cytotoxicity, harming healthy cells alongside cancerous ones, leading to severe side effects. While nanocarriers have emerged as a potential solution for targeted drug delivery, engineering a single nanocarrier that can efficiently cross the BBB and then specifically target glioma cells remains a significant hurdle. This paper aims to address this by developing a dual-targeting nanocarrier system that leverages the inherent properties of low-density lipoprotein (LDL) and a specific peptide ligand.

Methods

The researchers developed a T7 peptide-modified LDL (T7-LDL) nanocarrier system. The process involved:

  • LDL Isolation: Low-density lipoprotein (LDL) was isolated from human plasma using density gradient ultracentrifugation.
  • T7 Peptide Conjugation: A T7 peptide, known to bind to transferrin receptors (TfR) and facilitate BBB penetration, was synthesized with a cysteine residue. This peptide was then conjugated to NHS-PEG3500-Mal via a sulfhydryl-maleimide reaction. The resulting NHS-PEG3500-T7 was subsequently coupled to LDL particles through an N-hydrosuccinimide-amino coupling reaction.
  • Drug Loading: Vincristine sulfate (VCR), a chemotherapy drug, was loaded into both the modified (T7-LDL) and unmodified (LDL) particles.
  • Characterization: The physicochemical properties of the nanocarriers, including particle size, polydispersity index, encapsulation efficiency, drug loading efficiency, and zeta potential, were characterized using techniques like dynamic light scattering (DLS), transmission electron microscopy (TEM), and UV-Vis spectrophotometry. Stability was assessed in rat serum using a Turbiscan Lab Expert.
  • In Vitro BBB Model: A co-culture model of bEnd.3 (brain endothelial cells) and C6 (glioma cells) was established to mimic the BBB and assess the penetration efficiency of the nanocarriers.
  • Cellular Uptake Studies: Confocal laser scanning microscopy (CLSM) was used to evaluate the cellular uptake of Cy5.5-labeled T7-LDL and LDL in bEnd.3 and C6 cells, including experiments with excess free T7 peptide or LDL to elucidate the targeting mechanisms (TfR and LDLR mediation).
  • Cytotoxicity Assay: An MTT assay was performed to determine the in vitro cytotoxicity of blank nanocarriers, free VCR, VCR-loaded T7-LDL, and VCR-loaded LDL on C6 glioma cells.
  • In Vivo Studies:
    • Zebrafish BBB Model: Zebrafish were used to assess the in vivo brain targeting ability of Cy5.5-labeled T7-LDL and LDL.
  • Mice Models: Mice bearing intracranial C6 gliomas were used for ex vivo biodistribution studies (imaging of brain and major organs) and in vivo therapeutic efficacy assessments.
  • Therapeutic Efficacy: Tumor volume was monitored via MRI, and survival rates were analyzed using Kaplan-Meier curves. Histological analysis (HE staining) was also performed.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Dual Targeting Synergy: The combination of LDL's inherent ability to target brain endothelial cells and glioma cells (via LDLR) with the T7 peptide's TfR-targeting capability creates a powerful dual-targeting system. This synergy significantly enhances both BBB penetration and glioma cell recognition compared to LDL alone.
  • Natural Nanocarrier Advantage: Utilizing LDL, a naturally occurring lipoprotein, as a nanocarrier offers inherent biocompatibility and biosafety, circumventing potential toxicity issues associated with synthetic nanocarriers.
  • T7 Peptide Optimization: The study investigated the density of T7 peptide conjugation, finding that a 4% molar ratio provided optimal cellular uptake, suggesting a saturation point for TfR-mediated endocytosis.
  • Enhanced VCR Efficacy: T7-LDL demonstrated superior in vitro and in vivo antiglioma effects compared to free VCR and VCR-loaded LDL, highlighting the improved drug delivery and targeting.
  • BBB Penetration Mechanism: The in vivo zebrafish model provided a quick and effective way to demonstrate that T7-LDL significantly improves brain delivery compared to LDL alone.

Key Results

  • Nanocarrier Characterization: VCR-loaded T7-LDL particles were found to be approximately 30 nm in size with a narrow size distribution, suitable for circulation and tissue penetration. They also exhibited good stability in rat serum.
  • Cellular Uptake: T7-LDL showed significantly higher cellular uptake in both bEnd.3 and C6 cells compared to LDL, with uptake being mediated by both TfR and LDLR.
  • In Vitro Cytotoxicity: VCR-loaded T7-LDL exhibited enhanced cytotoxicity against C6 glioma cells compared to VCR-loaded LDL, with IC50 values of 42.8 ng/mL for T7-LDL versus 75.5 ng/mL for LDL.
  • In Vivo Brain Targeting: In zebrafish, T7-LDL showed a higher accumulation in the brain compared to LDL. In mice, ex vivo imaging confirmed higher T7-LDL accumulation in glioma regions.
  • Antiglioma Efficacy: In mice with intracranial gliomas, VCR-loaded T7-LDL significantly reduced tumor volume and prolonged median survival time (36 days) compared to physiological saline (18 days), free VCR (19 days), and VCR-loaded LDL (26 days).

Limitations and Future Work

  • Protein Corona: The authors acknowledge that plasma or serum proteins can associate with nanoparticles, forming a "protein corona" that can influence their behavior. While this was not evaluated in this study, it could affect in vivo performance. Future work should investigate the impact of protein corona on T7-LDL.
  • LDL Conformation: The study did not explicitly survey conformational changes of LDL after T7 peptide modification. However, the similar drug loading/release profiles and cytotoxicity suggest that the modification did not drastically alter LDL's fundamental properties.
  • Future Directions: The authors suggest that further studies are needed to improve surface engineering techniques for LDL and to explore the broader application of T7-LDL in glioma-targeted delivery. They also note that while LDL is generally safe, the amount injected might have a mild effect on cholesterol metabolism, suggesting the potential need for statin co-therapy in some cases.

Summary updated

Abstract

Therapeutic outcome for the treatment of glioma was often limited due to the non-targeted nature and low permeability of drugs across the blood-brain barrier (BBB). An ideal glioma-targeted delivery system need to traverse the BBB and then target glioma cells with adequate optimized physiochemical properties and biocompatibility. However, it is an enormous challenge to the researchers to engineer the above-mentioned features into a single nanocarrier particle. New frontiers in nanomedicine are advancing the research of new biomaterials. In this study, we demonstrate a strategy for glioma targeting by encapsulating vincristine sulfate (VCR) into a naturally available low-density lipoprotein particles (LDL)-based drug delivery system with the modification of T7 peptide ligand (T7-LDL). LDL, endogenous lipid transporters, can specifically bind to brain endothelial cells and glioma cells via interacting with the low-density lipoprotein receptors (LDLR). T7 is a seven-peptide ligand of transferrin receptors (TfR) capable of circumventing the BBB and then targeting glioma. By combining the dual-targeting delivery effect of T7 peptide and parent LDL, T7-LDL displayed higher glioma localization than that of parent LDL. After loading with VCR, T7-LDL showed the most favorable antiglioma effect in vitro and in vivo. These results demonstrated that T7-LDL is an important potential drug delivery system for glioma-targeted therapy.
BibTeX
@inproceedings{liang2018enhanced,
  author = {Meng Liang and Chun‐Hong Gao and Yuli Wang and Wei Gong and Shiyao Fu and Lin Cui and Zhenhan Zhou and Xiaoyang Chu and Yue Zhang and Qianqian Liu and Xiong Zhao and Baoquan Zhao and Meiyan Yang and Zhiping Li and Chunrong Yang and Xiangyang Xie and Yang Yang and Chunsheng Gao},
  title = {{Enhanced blood–brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles}},
  booktitle = {Drug},
  year = {2018},
  doi = {10.1080/10717544.2018.1494223},
}
Figure